{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:02:05Z","timestamp":1790938925238,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ahj.2011.05.012","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T05:21:49Z","timestamp":1310620909000},"page":"201-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Current therapeutics and practical management strategies for pulmonary arterial hypertension"],"prefix":"10.1016","volume":"162","author":[{"given":"Richa","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2011.05.012_bb0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0020","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0025","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2010.11.020","article-title":"Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective","volume":"57","author":"Gomberg-Maitland","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0030","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","article-title":"Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension","volume":"179","author":"Fisher","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0040","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1378\/chest.10-1269","article-title":"The inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice","volume":"139","author":"Rich","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ahj.2011.05.012_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.80.2.353","article-title":"Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension","volume":"80","author":"Eysmann","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Galie","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCIMAGING.109.919779","article-title":"Understanding late gadolinium enhancement in pulmonary hypertension","volume":"3","author":"Bradlow","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2011.05.012_bb0065","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1378\/chest.119.6.1761","article-title":"Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension. Noninvasive monitoring using MRI","volume":"119","author":"Marcus","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0070","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/eurheartj\/14.11.1524","article-title":"Magnetic resonance assessment of the pulmonary arterial trunk anatomy, flow, pulsatility and distensibility","volume":"14","author":"Paz","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0075","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/ajrccm.150.4.7921439","article-title":"Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging","volume":"150","author":"Tardivon","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0080","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehi328","article-title":"Contrast enhanced\u2013cardiovascular magnetic resonance imaging in patients with pulmonary hypertension","volume":"26","author":"Blyth","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0085","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0095","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.114.3.787","article-title":"The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension","volume":"114","author":"Rich","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0735-1097(86)80277-7","article-title":"Regression in thromboembolic type of primary pulmonary hypertension during 2 1\/2 years of antithrombotic therapy","volume":"7","author":"Cohen","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0130","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0145","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1164\/rccm.200204-330OC","article-title":"Prognositc factors for survival in human immunodeficiency virus\u2013associated pulmonary arterial hypertension","volume":"167","author":"Nunes","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-2006-947294","article-title":"Evolving dilemmas and management of portopulmonary hypertension","volume":"26","author":"Krowka","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ahj.2011.05.012_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2008.01811.x","article-title":"Guidelines for the prevention of central venous catheter\u2013related blood stream infections with prostanoid therapy for pulmonary arterial hypertension","volume":"62","author":"Doran","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2011.05.012_bb0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0170","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0180","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0190","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0195","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0200","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0205","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.05.012_bb0210","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0215","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2011.05.012_bb0225","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1054\/jcaf.2002.126486","article-title":"Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?","volume":"8","author":"Teerlink","year":"2002","journal-title":"J Card Fail"},{"issue":"Suppl 48","key":"10.1016\/j.ahj.2011.05.012_bb0230","doi-asserted-by":"crossref","first-page":"408S","DOI":"10.1042\/CS103S408S","article-title":"Effect of the novel endothelin (A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery","volume":"103","author":"Vatter","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ahj.2011.05.012_bb0235","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0240","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0245","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Nagendran","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0250","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0255","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1097\/00002030-200207260-00021","article-title":"Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension","volume":"16","author":"Carlsen","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2011.05.012_bb0260","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1183\/09031936.00039007","article-title":"Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension","volume":"30","author":"Reichenberger","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0265","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.05.012_bb0270","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.transproceed.2008.05.055","article-title":"Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients","volume":"40","author":"De Santo","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ahj.2011.05.012_bb0275","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0280","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.healun.2003.09.024","article-title":"Sildenafil for pulmonary hypertension after heart transplantation","volume":"23","author":"Kulkarni","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ahj.2011.05.012_bb0285","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0290","unstructured":"National Heart L, and Blood Institute (NHLBI). Evaluating the effectiveness of Sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. NLM identifier: NCT00763867: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00763867; 2011 Apr 20."},{"key":"10.1016\/j.ahj.2011.05.012_bb0295","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0300","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0310","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0315","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial","volume":"49","author":"Wang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0320","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0325","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0330","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0335","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0340","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2011.05.012_bb0345","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/physiolgenomics.00169.2007","article-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","volume":"33","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.ahj.2011.05.012_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2007.01497.x","article-title":"Pulmonary hypertension and the serotonin hypothesis: where are we now?","author":"MacLean","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.ahj.2011.05.012_bb0355","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1161\/01.CIR.0000127375.56172.92","article-title":"Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension","volume":"109","author":"MacLean","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.05.012_bb0360","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0365","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1183\/09031936.00070209","article-title":"Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension","volume":"35","author":"Sztrymf","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0370","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/eurheartj\/ehm567","article-title":"Right coronary artery flow impairment in patients with pulmonary hypertension","volume":"29","author":"van Wolferen","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.05.012_bb0375","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1097\/01.CCM.0000280433.74246.9E","article-title":"Management strategies for patients with pulmonary hypertension in the intensive care unit","volume":"35","author":"Zamanian","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0380","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/01.CCM.0000120052.77953.07","article-title":"Effects of norepinephrine and dobutamine on pressure load\u2013induced right ventricular failure","volume":"32","author":"Kerbaul","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ahj.2011.05.012_bb0385","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1378\/chest.98.5.1102","article-title":"The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension","volume":"98","author":"Rich","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2011.05.012_bb0390","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jacc.2009.04.016","article-title":"Interventional and surgical modalities of treatment in pulmonary hypertension","volume":"54","author":"Keogh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.05.012_bb0395","series-title":"Pulmonary hypertension therapy","author":"Hill","year":"2006"},{"key":"10.1016\/j.ahj.2011.05.012_bb0400","doi-asserted-by":"crossref","first-page":"R169","DOI":"10.1186\/cc9264","article-title":"Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review","volume":"14","author":"Price","year":"2010","journal-title":"Crit Care"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311003991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311003991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:44:32Z","timestamp":1757569472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311003991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0002870311003991"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2011.05.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current therapeutics and practical management strategies for pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2011.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}